Bringing a new drug from the lab to the pharmacy in the United States involves two FDA submissions: the Investigational New Drug application (IND) versus the New Drug Application (NDA).
These two filings dictate which documents teams author, which data they collect, which regulatory clocks they manage, and where the submission timeline holds firm or slips by months. The IND opens the door to human testing. The NDA requests marketing authorization. Between them lie years of clinical trials, safety monitoring, and regulatory documentation.
For regulatory and medical writing teams, the challenge isn't just understanding what each submission contains. It's compressing the years of documentation work that connects the two.
What Does IND Stand For?
IND stands for Investigational New Drug application. It is the formal submission a sponsor files with the FDA under 21 CFR 312 to obtain authorization to begin testing a drug in human subjects.
The IND is not a marketing application. Rather, it is the regulatory gateway to clinical trials, and no Phase I study may legally commence without one.
An IND application is built around several core components:
Preclinical Pharmacology and Toxicology Data: Animal pharmacology and toxicology studies demonstrate that the drug is reasonably safe for initial human administration, as required under 21 CFR 312.23(a)(8).
Chemistry, Manufacturing, and Controls (CMC) Information: CMC data confirm the sponsor can manufacture batches of the investigational product with consistent quality across the proposed trial period.
Clinical Protocols: Each proposed study protocol details design, dosing, endpoints, and safety monitoring plans, accompanied by investigator qualifications captured on Form FDA 1572.
Investigator's Brochure: The IB consolidates everything the principal investigator needs to understand the product's pharmacology, toxicology, and prior human experience.
Form FDA 1571: The IND cover form, signed by the sponsor, accompanies every IND submission and amendment throughout the application's life.
Once the IND is received, the FDA has 30 calendar days to review the package. If no clinical hold is issued within that window, the sponsor may proceed with the trial under 21 CFR 312.40. The agency's review focuses on whether participants will be exposed to unreasonable risk and whether the proposed study is scientifically sound.
The IND remains active throughout the clinical development program, accumulating protocol amendments, new investigator forms, and annual safety reports as the molecule progresses from Phase I through Phase III.
The Meaning of NDA in the Pharma Industry
The NDA is the marketing application a sponsor files with the FDA under 21 CFR 314.50 to request authorization to commercialize a drug in the United States. Where the IND asks whether a drug can be tested in people, the NDA asks whether it can be sold to them, and the evidentiary standard is set accordingly.
An NDA dossier is far more extensive than an IND, typically including:
Complete Clinical Trial Data: All adequate and well-controlled studies from Phase I through Phase III are submitted, including efficacy and safety results, individual case report forms, and patient-level tabulations.
CMC Documentation at Commercial Scale: Full CMC covers commercial manufacturing processes, in-process controls, stability data, and validated analytical procedures.
Integrated Safety and Efficacy Summaries: CTD Module 2.5 Clinical Overview, Module 2.7 Clinical Summaries, and Module 2.4 Nonclinical Overview consolidate years of evidence into reviewer-ready synthesis documents.
Proposed Product Labeling: Annotated draft labeling, including any required Medication Guide, traces each statement back to supporting evidence in the technical sections.
Form FDA 356 h: The application form for NDAs and BLAs is accompanied by patent and exclusivity information, financial disclosure forms, and pediatric study commitments.
NDAs are submitted in eCTD format, organized across the five CTD modules per ICH M 4. The FDA has 60 days from receipt to determine whether the application is complete and ready for substantive review. Once filed, the standard review timeline for new molecular entities is 10 months from the 60-day filing date. Priority review compresses this to six months for drugs addressing unmet medical needs, per PDUFA VII commitments.
A successful NDA results in full marketing authorization, enabling commercial distribution, promotion, and sale of the drug in the United States.
IND vs NDA in FDA: Key Differences at a Glance
Both submissions are mandatory milestones governed by the FDA, but they differ across every material dimension: purpose, timing, evidentiary scope, and regulatory consequence.
| Dimension | IND | NDA |
| Full Name | Investigational New Drug Application | New Drug Application |
| Purpose | Authorization to begin clinical trials in humans | Authorization to commercially market the drug |
| Timing Filed | After preclinical studies, before first-in-human dosing | After completion of all clinical phases (I to III) |
| FDA Review Timeline | 30 calendar days (default-effective unless clinical hold) | 60-day filing review, then 10 months standard or six months priority |
| FDA Form | Form FDA 1571 (with Form FDA 1572 for investigators) | Form FDA 356 h |
| Data Required | Preclinical pharm and tox, CMC, protocols, IB, investigator data | Full clinical data, commercial CMC, integrated summaries, proposed labeling |
| Regulatory Focus | Subject safety and scientific soundness of trial design | Benefit-risk profile across the full development program |
| Submission Format | eCTD (mandatory for commercial INDs since 2018) | eCTD across five CTD modules per ICH M 4 |
| Outcome | Permission to initiate clinical trials | Full marketing authorization in the United States |
| Post-Approval Obligations | IND amendments, IND safety reports, annual reports, DSURs | Post-marketing commitments, PSURs/PBRERs, REMS where required |
The table above shows that NDA and IND are not the same thing. They are distinct regulatory filings that serve different purposes at different points in the drug development timeline.
What is the Difference Between NDA and IND Drugs?
The difference between NDA and IND drugs comes down to regulatory status.
A drug under an IND is investigational: it has not been approved for marketing and is being studied in clinical trials to generate safety and efficacy data.
A drug covered by an approved NDA is a marketed product. This means that the FDA has reviewed the full body of clinical evidence and determined that the benefits outweigh the risks for the intended patient population.
From IND to NDA: A Documentation Lifecycle, Not Just Two Submissions
The IND and NDA are not isolated documents. They are anchors at opposite ends of a decade-long documentation lifecycle, with hundreds of interconnected regulatory documents generated in between. Each one must be internally consistent, cross-referenced to source data, and eCTD-ready at the moment of submission.
The documents produced between IND filing and NDA submission typically include:
Investigator's Brochures and IB Updates: Refreshed at least annually and after each major safety or efficacy signal, the IB stays current across the full program.
Phase I to III Protocols and Amendments: Each new study, dose escalation, and design change requires a protocol or a protocol amendment, as required under 21 CFR 312.30.
Clinical Study Reports: Every completed trial generates an ICH E 3-compliant CSR, the single largest authoring effort in late-stage development.
DSUR Aggregate Safety Reports: Development Safety Update Reports synthesize emerging safety data across all ongoing trials on an annual cycle.
Patient Safety Narratives and Lay Summaries: Required for serious adverse events and, increasingly, for trial transparency obligations under regional regulations.
CTD Module 2 Integrated Summaries: Module 2.5 Clinical Overview, Module 2.7 Clinical Summaries (2.7.3 Efficacy, 2.7.4 Safety), Module 2.6 Nonclinical Summaries, and Module 2.3 Quality Overall Summary form the analytical layer that NDA reviewers read first.
A typical NDA dossier can run into thousands of pages of evidence synthesized from years of trials, safety reports, and scientific literature.
The question that defines submission timelines is not how many people you put on each document. What matters is how consistently those documents agree with one another at the moment the filing goes through the FDA's Electronic Submissions Gateway.
Where Documentation Bottlenecks Form Between IND and NDA
The places where IND-to-NDA programs lose time are predictable, but they are rarely fixed by adding headcount. Each stage carries its own authoring pressure, and the bottlenecks compound.
IND Filing Stage
Early in the IND phase, nonclinical written summaries and initial protocol drafting are routinely underestimated. Teams build the first Module 2.6 and Module 4 documents while CMC sections are still changing. Source data shifts, versions diverge, and the first patient is enrolled later than planned.
Phase I and II: Parallel Accumulation
During Phase I and II, the authoring load shifts to Investigator's Brochure updates, individual patient safety narratives, and annual DSUR submissions. Manual workflows that worked for one trial begin to fail across three or four.
Statistical programmers and medical writers spend their time reconciling TLF outputs against narrative summaries rather than analyzing the data those outputs describe.
Phase III: Peak Authoring Load
Phase III brings the heaviest concurrent writing load in the entire development lifecycle. Full CSR generation runs in parallel with protocol amendments across multiple studies, and CTD Module 2.5 and 2.7 integrated summaries begin drafting before the final database lock.
NDA Compilation: Where Delays Crystallize
NDA compilation is where the most avoidable delays sit. Cross-module consistency checks, eCTD validation, and quality control across all five modules surface inconsistencies between Module 5 study reports and Module 2 summaries.
A single mismatch between a CSR narrative and the Clinical Summary can trigger an FDA query that resets the review clock by weeks.
The root cause is rarely the individual writer's skill. Manual authoring workflows were engineered for an era of smaller datasets, fewer simultaneous documents, and less demanding regulatory scrutiny than today's submissions require. An automation writing tool for drug development addresses that structural gap directly at the workflow level, not the individual document.
